Letrozol Sun

Letrozole, the active ingredient in Letrozol Sun, is a aromatase inhibitor presented as an oral tablet for oral use. It reduces estrogen production and is used in the treatment of hormone receptor‑positive breast cancer in postmenopausal women. It is indicated for postmenopausal women whose tumors express estrogen receptors, helping to slow disease progression.

GNH USA supplies Letrozol Sun as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU quality standards and providing the product to oncology centres, hospitals and pharmacies worldwide.

Letrozole is an aromatase inhibitor used in hormone‑dependent breast cancer therapy. - Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen‑driven tumor growth and delays disease progression. - Adjuvant treatment of early‑stage disease: improves disease‑free survival after surgery. - Metastatic breast cancer: helps control tumor spread and prolongs overall survival.

Adverse reactions may occur with Letrozol Sun and are categorized by frequency.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching in limbs and back. - Nausea: mild to moderate upset stomach. - Fatigue: persistent tiredness. - Headache: mild to moderate intensity. - Increased sweating: excessive perspiration.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes. - Bone fracture: increased risk of osteoporosis‑related breaks. - Pulmonary embolism: sudden shortness of breath and chest pain. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Elevated cholesterol: significant rise in blood lipid levels.

Patients should be counseled on safety measures before starting Letrozol Sun. - Monitor bone mineral density: assess risk of osteoporosis and consider supplementation. - Check liver enzymes: perform baseline and periodic hepatic function tests. - Assess cardiovascular health: evaluate for thrombosis risk factors. - Contraindicated in pregnancy: avoid use in pregnant women due to teratogenicity. - Counsel on menopausal symptoms: provide strategies for managing hot flashes and sweating. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Letrozol Sun may interact with other medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce letrozole exposure. - Tamoxifen: antagonistic hormonal effects can diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may increase bleeding tendency. - Statins (e.g., simvastatin): potential rise in plasma concentrations. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may affect metabolism and plasma levels.